These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

384 related articles for article (PubMed ID: 36560595)

  • 21. Accumulation of integrase strand transfer inhibitor resistance mutations confers high-level resistance to dolutegravir in non-B subtype HIV-1 strains from patients failing raltegravir in Uganda.
    Ndashimye E; Avino M; Olabode AS; Poon AFY; Gibson RM; Li Y; Meadows A; Tan C; Reyes PS; Kityo CM; Kyeyune F; Nankya I; Quiñones-Mateu ME; Arts EJ
    J Antimicrob Chemother; 2020 Dec; 75(12):3525-3533. PubMed ID: 32853364
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Durable suppression of HIV-1 with resistance mutations to integrase inhibitors by dolutegravir following drug washout.
    Osman N; Mesplède T; Oliveira M; Hassounah S; Wainberg MA; Brenner BG
    AIDS; 2018 Aug; 32(13):1773-1780. PubMed ID: 29894388
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Structural Comparison of Diverse HIV-1 Subtypes using Molecular Modelling and Docking Analyses of Integrase Inhibitors.
    Isaacs D; Mikasi SG; Obasa AE; Ikomey GM; Shityakov S; Cloete R; Jacobs GB
    Viruses; 2020 Aug; 12(9):. PubMed ID: 32858802
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Primary resistance to integrase inhibitors in Shenzhen.
    Zhu Y; Huang Y; Zheng C; Tang J; Zeng G; Xie W; Wang H; Zhang L; Liu S; Zhang Y; Tan W; Tan J; Jiang L; He Y; Xu L; Yang Z; Zhao J
    J Antimicrob Chemother; 2023 Feb; 78(2):546-549. PubMed ID: 36585770
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Effect of HIV-1 integrase resistance mutations when introduced into SIVmac239 on susceptibility to integrase strand transfer inhibitors.
    Hassounah SA; Mesplède T; Quashie PK; Oliveira M; Sandstrom PA; Wainberg MA
    J Virol; 2014 Sep; 88(17):9683-92. PubMed ID: 24920794
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Combination of two pathways involved in raltegravir resistance confers dolutegravir resistance.
    Malet I; Thierry E; Wirden M; Lebourgeois S; Subra F; Katlama C; Deprez E; Calvez V; Marcelin AG; Delelis O
    J Antimicrob Chemother; 2015 Oct; 70(10):2870-80. PubMed ID: 26205139
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Differences among HIV-1 subtypes in drug resistance against integrase inhibitors.
    Han YS; Mesplède T; Wainberg MA
    Infect Genet Evol; 2016 Dec; 46():286-291. PubMed ID: 27353185
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Comparative Clinical Pharmacokinetics and Pharmacodynamics of HIV-1 Integrase Strand Transfer Inhibitors.
    Podany AT; Scarsi KK; Fletcher CV
    Clin Pharmacokinet; 2017 Jan; 56(1):25-40. PubMed ID: 27317415
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Characterization of the Drug Resistance Profiles of Integrase Strand Transfer Inhibitors in Simian Immunodeficiency Virus SIVmac239.
    Hassounah SA; Liu Y; Quashie PK; Oliveira M; Moisi D; Brenner BG; Sandstrom PA; Mesplède T; Wainberg MA
    J Virol; 2015 Dec; 89(23):12002-13. PubMed ID: 26378179
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Natural polymorphism S119R of HIV-1 integrase enhances primary INSTI resistance.
    Hachiya A; Ode H; Matsuda M; Kito Y; Shigemi U; Matsuoka K; Imamura J; Yokomaku Y; Iwatani Y; Sugiura W
    Antiviral Res; 2015 Jul; 119():84-8. PubMed ID: 25956162
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Resistance mutations outside the integrase coding region have an effect on human immunodeficiency virus replicative fitness but do not affect its susceptibility to integrase strand transfer inhibitors.
    Weber J; Rose JD; Vazquez AC; Winner D; Margot N; McColl DJ; Miller MD; Quiñones-Mateu ME
    PLoS One; 2013; 8(6):e65631. PubMed ID: 23776513
    [TBL] [Abstract][Full Text] [Related]  

  • 32. High-level resistance to bictegravir and cabotegravir in subtype A- and D-infected HIV-1 patients failing raltegravir with multiple resistance mutations.
    Ndashimye E; Li Y; Reyes PS; Avino M; Olabode AS; Kityo CM; Kyeyune F; Nankya I; Quiñones-Mateu ME; Barr SD; Arts EJ
    J Antimicrob Chemother; 2021 Oct; 76(11):2965-2974. PubMed ID: 34453542
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Biochemical analysis of the role of G118R-linked dolutegravir drug resistance substitutions in HIV-1 integrase.
    Quashie PK; Mesplède T; Han YS; Veres T; Osman N; Hassounah S; Sloan RD; Xu HT; Wainberg MA
    Antimicrob Agents Chemother; 2013 Dec; 57(12):6223-35. PubMed ID: 24080645
    [TBL] [Abstract][Full Text] [Related]  

  • 34. A New Mechanism of Resistance of Human Immunodeficiency Virus Type 2 to Integrase Inhibitors: A 5-Amino-Acid Insertion in the Integrase C-Terminal Domain.
    Le Hingrat Q; Collin G; Lê M; Peytavin G; Visseaux B; Bertine M; Tubiana R; Karmochkine M; Valin N; Collin F; Lemaignen A; Bernard L; Damond F; Matheron S; Descamps D; Charpentier C;
    Clin Infect Dis; 2019 Aug; 69(4):657-667. PubMed ID: 30383215
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Prevalence and determinants of resistance mutations in HIV-1-infected patients exposed to integrase inhibitors in a large Italian cohort.
    Modica S; Rossetti B; Lombardi F; Lagi F; Maffeo M; D'Autilia R; Pecorari M; Vicenti I; Bruzzone B; Magnani G; Paolucci S; Francisci D; Penco G; Sacchini D; Zazzi M; De Luca A; Di Biagio A
    HIV Med; 2019 Feb; 20(2):137-146. PubMed ID: 30461149
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Effects of different integrase strand transfer inhibitors on body weight in patients with HIV/AIDS: a network meta-analysis.
    Bai R; Lv S; Wu H; Dai L
    BMC Infect Dis; 2022 Feb; 22(1):118. PubMed ID: 35114968
    [TBL] [Abstract][Full Text] [Related]  

  • 37. The S230R Integrase Substitution Associated With Virus Load Rebound During Dolutegravir Monotherapy Confers Low-Level Resistance to Integrase Strand-Transfer Inhibitors.
    Pham HT; Labrie L; Wijting IEA; Hassounah S; Lok KY; Portna I; Goring ME; Han Y; Lungu C; van der Ende ME; Brenner BG; Boucher CA; Rijnders BJA; van Kampen JJA; Mesplède T; Wainberg MA
    J Infect Dis; 2018 Jul; 218(5):698-706. PubMed ID: 29617824
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Evaluation of HIV-1 integrase resistance emergence and evolution in patients treated with integrase inhibitors.
    Scutari R; Alteri C; Vicenti I; Di Carlo D; Zuccaro V; Incardona F; Borghi V; Bezenchek A; Andreoni M; Antinori A; Perno CF; Cascio A; De Luca A; Zazzi M; Santoro MM;
    J Glob Antimicrob Resist; 2020 Mar; 20():163-169. PubMed ID: 31330378
    [TBL] [Abstract][Full Text] [Related]  

  • 39. The G118R plus R263K Combination of Integrase Mutations Associated with Dolutegravir-Based Treatment Failure Reduces HIV-1 Replicative Capacity and Integration.
    Xiao MA; Cleyle J; Yoo S; Forrest M; Krullaars Z; Pham HT; Mesplède T
    Antimicrob Agents Chemother; 2023 May; 67(5):e0138622. PubMed ID: 37071019
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Effects of raltegravir or elvitegravir resistance signature mutations on the barrier to dolutegravir resistance in vitro.
    Seki T; Suyama-Kagitani A; Kawauchi-Miki S; Miki S; Wakasa-Morimoto C; Akihisa E; Nakahara K; Kobayashi M; Underwood MR; Sato A; Fujiwara T; Yoshinaga T
    Antimicrob Agents Chemother; 2015 May; 59(5):2596-606. PubMed ID: 25691633
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 20.